Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Raw Materials (2016 - 2026)

Phibro Animal Health has reported Raw Materials over the past 13 years, most recently at $178.5 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 22.34% year-over-year to $178.5 million; the TTM value through Dec 2025 reached $178.5 million, up 22.34%, while the annual FY2025 figure was $162.6 million, 123.39% up from the prior year.
  • Raw Materials for Q4 2025 was $178.5 million at Phibro Animal Health, up from $166.4 million in the prior quarter.
  • Over five years, Raw Materials peaked at $178.5 million in Q4 2025 and troughed at $59.8 million in Q2 2021.
  • A 5-year average of $99.5 million and a median of $84.8 million in 2022 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: fell 20.21% in 2023 and later skyrocketed 123.39% in 2025.
  • Year by year, Raw Materials stood at $71.3 million in 2021, then surged by 35.44% to $96.6 million in 2022, then decreased by 20.21% to $77.0 million in 2023, then skyrocketed by 89.35% to $145.9 million in 2024, then increased by 22.34% to $178.5 million in 2025.
  • Business Quant data shows Raw Materials for PAHC at $178.5 million in Q4 2025, $166.4 million in Q3 2025, and $162.6 million in Q2 2025.